Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJesper Gromada, Haruka Okamoto, Stephen Jaspers, Joyce Harp
Estimating the term…
Provided herein are methods of treating a patient with severe insulin resistance. The methods comprise administering to a patient in need thereof a therapeutic amount of a GCG/GCGR signaling pathway inhibitor, such that blood glucose or beta-hydroxybutyrate levels are lowered or that the severe insulin resistance is mediated, or a condition or disease characterized by severe insulin resistance is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The GCG/GCGR signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from severe insulin resistance.
A method for treating a patient having severe insulin resistance, the method comprising administering a therapeutically effective amount of a composition comprising a glucagon (GCG) inhibitor or a glucagon receptor (GCGR) antagonist, such that blood glucose levels or levels of ketone bodies are lowered or that the condition or disease is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity, wherein:
(canceled)
(canceled)
15-17. (canceled)
A method of treating a patient with severe insulin resistance,
(canceled)
(canceled)
35-37. (canceled)
A method of reducing the amount and/or dosage of insulin necessary to treat a patient with severe insulin resistance, wherein the patient exhibits severe insulin resistance and elevated levels of blood glucose, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a GCG inhibitor or a GCGR antagonist, wherein:
(canceled)
(canceled)
56-58. (canceled)
61-63. (canceled)
A method of increasing β-cell mass in a patient having severe insulin resistance, the method comprising administering to the patient a therapeutically effective amount of a composition comprising an inhibitor of GCGR signaling, such that β-cell mass increases relative to the β-cell mass prior to treatment;
Dependencies are inferred from the claim text.